🚀 VC round data is live in beta, check it out!
Dimed SA Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dimed SA and similar public comparables like Great Tree Pharmacy, Cawachi, YSB, JZJ Chain Drugstore and more.
Dimed SA Overview
About Dimed SA
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. Its segments are divided into Retail, Wholesale and Corporate. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. The Wholesale segment is the distributor of drugs in Brazil. The Corporate segment includes Wholesale and Retail, as well as the subsidiary Lifar. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
Founded
1967
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$623M
Dimed SA Financials
Dimed SA reported last 12-month revenue of $1B and EBITDA of $63M.
In the same LTM period, Dimed SA generated $63M in EBITDA and $27M in net income.
Revenue (LTM)
Dimed SA P&L
In the most recent fiscal year, Dimed SA reported revenue of $939M and EBITDA of $81M.
Dimed SA expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $939M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $299M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 32% | XXX | XXX | XXX |
| EBITDA | $63M | XXX | $81M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $27M | XXX | $20M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | — | — | $90M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dimed SA Stock Performance
Dimed SA has current market cap of $431M, and enterprise value of $623M.
Market Cap Evolution
Dimed SA's stock price is $2.89.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $623M | $431M | (0.6%) | XXX | XXX | XXX | $0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDimed SA Valuation Multiples
Dimed SA trades at 0.6x EV/Revenue multiple, and 9.8x EV/EBITDA.
EV / Revenue (LTM)
Dimed SA Financial Valuation Multiples
As of March 7, 2026, Dimed SA has market cap of $431M and EV of $623M.
Equity research analysts estimate Dimed SA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dimed SA has a P/E ratio of 16.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $431M | XXX | $431M | XXX | XXX | XXX |
| EV (current) | $623M | XXX | $623M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.8x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBIT | 23.5x | XXX | 16.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.1x | XXX | XXX | XXX |
| P/E | 16.0x | XXX | 21.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 49.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dimed SA Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dimed SA Margins & Growth Rates
Dimed SA's revenue in the last 12 month grew by 15%.
Dimed SA's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dimed SA's rule of X is 43% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Dimed SA Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | (25%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 43% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dimed SA Public Comps
See public comps and valuation multiples for other Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Great Tree Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Cawachi | XXX | XXX | XXX | XXX | XXX | XXX |
| YSB | XXX | XXX | XXX | XXX | XXX | XXX |
| JZJ Chain Drugstore | XXX | XXX | XXX | XXX | XXX | XXX |
| Fangzhou | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dimed SA M&A Activity
Dimed SA acquired XXX companies to date.
Last acquisition by Dimed SA was on XXXXXXXX, XXXXX. Dimed SA acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dimed SA
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDimed SA Investment Activity
Dimed SA invested in XXX companies to date.
Dimed SA made its latest investment on XXXXXXXX, XXXXX. Dimed SA invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dimed SA
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dimed SA
| When was Dimed SA founded? | Dimed SA was founded in 1967. |
| Where is Dimed SA headquartered? | Dimed SA is headquartered in Brazil. |
| Is Dimed SA publicly listed? | Yes, Dimed SA is a public company listed on B3. |
| What is the stock symbol of Dimed SA? | Dimed SA trades under PNVL3 ticker. |
| When did Dimed SA go public? | Dimed SA went public in 1995. |
| Who are competitors of Dimed SA? | Dimed SA main competitors are Great Tree Pharmacy, Cawachi, YSB, JZJ Chain Drugstore. |
| What is the current market cap of Dimed SA? | Dimed SA's current market cap is $431M. |
| What is the current revenue of Dimed SA? | Dimed SA's last 12 months revenue is $1B. |
| What is the current revenue growth of Dimed SA? | Dimed SA revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Dimed SA? | Current revenue multiple of Dimed SA is 0.6x. |
| Is Dimed SA profitable? | Yes, Dimed SA is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dimed SA? | Dimed SA's last 12 months EBITDA is $63M. |
| What is Dimed SA's EBITDA margin? | Dimed SA's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Dimed SA? | Current EBITDA multiple of Dimed SA is 9.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.